日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

一项 II 期随机、双盲、安慰剂对照研究，评估全人源抗 CXCL10 单克隆抗体 MDX-1100 与甲氨蝶呤联合治疗类风湿关节炎患者的疗效和安全性

期刊:Arthritis and Rheumatism
影响因子:11.4
doi:10.1002/art.34330
Michael Yellin, Igor Paliienko, Andra Balanescu, Semen Ter-Vartanian, Vira Tseluyko, Li-An Xu, Xiaolu Tao, Pina M Cardarelli, Heidi Leblanc, Geoff Nichol, Codrina Ancuta, Rodica Chirieac, Allison Luo
免疫
关节炎
发表日期：2024
文献求助 收藏

Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment

监测药物和抗药物浓度：对于接受生物制剂治疗且在接受稳定生物制剂治疗期间反应不足的类风湿关节炎患者的合理方法

期刊:Biomed Research International
影响因子:2.6
doi:10.1155/2014/702701
Diana Mazilu, Daniela Opriş, Cecilia Gainaru, Mihaela Iliuta, Natalia Apetrei, Giorgiana Luca, Andreea Borangiu, Tania Gudu, Alexandra Peltea, Laura Groseanu, Cosmin Constantinescu, Ioana Saulescu, Violeta Bojinca, Andra Balanescu, Denisa Predeteanu, Ruxandra Ionescu
免疫
关节炎
发表日期：2014
文献求助 收藏